Selected research
Market Analysis & Forecast
Global Live Vaccines Market Analysis and Forecast 2026-2032
Market perspective
The global Live Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Live Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Live Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Live Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Live Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global manufacturers of Live Vaccines include Astellas Pharma, Emergent BioSolutions, AstraZeneca, GlaxoSmithKline, Pfizer, Merck and Novartis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Live Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Live Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Live Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Live Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Live Vaccines sales, projected growth trends, production technology, application and end-user industry.
Live Vaccines Segment by Company
Astellas Pharma
Emergent BioSolutions
AstraZeneca
GlaxoSmithKline
Pfizer
Merck
Novartis
Live Vaccines Segment by Type
Monovalent Live Vaccines
Multivalent Live Vaccines
Live Vaccines Segment by Application
Adults
Children
Live Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Live Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Live Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Live Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Vaccines sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Live Vaccines
- Multivalent Live Vaccines
Applications
- Adults
- Children
Companies covered
- Astellas Pharma
- Emergent BioSolutions
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Merck
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Live Vaccines Market by Type
- 1.2.1 Global Live Vaccines Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Monovalent Live Vaccines
- 1.2.3 Multivalent Live Vaccines
- 1.3 Live Vaccines Market by Application
- 1.3.1 Global Live Vaccines Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Adults
- 1.3.3 Children
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Live Vaccines Market Dynamics
- 2.1 Live Vaccines Industry Trends
- 2.2 Live Vaccines Industry Drivers
- 2.3 Live Vaccines Industry Opportunities and Challenges
- 2.4 Live Vaccines Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Live Vaccines Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Live Vaccines Revenue by Region
- 3.2.1 Global Live Vaccines Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Live Vaccines Revenue by Region (2021-2026)
- 3.2.3 Global Live Vaccines Revenue by Region (2027-2032)
- 3.2.4 Global Live Vaccines Revenue Market Share by Region (2021-2032)
- 3.3 Global Live Vaccines Sales Estimates and Forecasts 2021-2032
- 3.4 Global Live Vaccines Sales by Region
- 3.4.1 Global Live Vaccines Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Live Vaccines Sales by Region (2021-2026)
- 3.4.3 Global Live Vaccines Sales by Region (2027-2032)
- 3.4.4 Global Live Vaccines Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Live Vaccines Revenue by Manufacturers
- 4.1.1 Global Live Vaccines Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Live Vaccines Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Live Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Live Vaccines Sales by Manufacturers
- 4.2.1 Global Live Vaccines Sales by Manufacturers (2021-2026)
- 4.2.2 Global Live Vaccines Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Live Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Live Vaccines Sales Price by Manufacturers (2021-2026)
- 4.4 Global Live Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Live Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Live Vaccines Manufacturers, Product Type & Application
- 4.7 Global Live Vaccines Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Live Vaccines Market CR5 and HHI
- 4.8.2 2025 Live Vaccines Tier 1, Tier 2, and Tier 3
5 Live Vaccines Market by Type
- 5.1 Global Live Vaccines Revenue by Type
- 5.1.1 Global Live Vaccines Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Live Vaccines Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Live Vaccines Revenue Market Share by Type (2021-2032)
- 5.2 Global Live Vaccines Sales by Type
- 5.2.1 Global Live Vaccines Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Live Vaccines Sales by Type (2021-2032) & (k units)
- 5.2.3 Global Live Vaccines Sales Market Share by Type (2021-2032)
- 5.3 Global Live Vaccines Price by Type
6 Live Vaccines Market by Application
- 6.1 Global Live Vaccines Revenue by Application
- 6.1.1 Global Live Vaccines Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Live Vaccines Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Live Vaccines Revenue Market Share by Application (2021-2032)
- 6.2 Global Live Vaccines Sales by Application
- 6.2.1 Global Live Vaccines Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Live Vaccines Sales by Application (2021-2032) & (k units)
- 6.2.3 Global Live Vaccines Sales Market Share by Application (2021-2032)
- 6.3 Global Live Vaccines Price by Application
7 Company Profiles
- 7.1 Astellas Pharma
- 7.1.1 Astellas Pharma Company Information
- 7.1.2 Astellas Pharma Business Overview
- 7.1.3 Astellas Pharma Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 Astellas Pharma Live Vaccines Product Portfolio
- 7.1.5 Astellas Pharma Recent Developments
- 7.2 Emergent BioSolutions
- 7.2.1 Emergent BioSolutions Company Information
- 7.2.2 Emergent BioSolutions Business Overview
- 7.2.3 Emergent BioSolutions Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 Emergent BioSolutions Live Vaccines Product Portfolio
- 7.2.5 Emergent BioSolutions Recent Developments
- 7.3 AstraZeneca
- 7.3.1 AstraZeneca Company Information
- 7.3.2 AstraZeneca Business Overview
- 7.3.3 AstraZeneca Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.3.4 AstraZeneca Live Vaccines Product Portfolio
- 7.3.5 AstraZeneca Recent Developments
- 7.4 GlaxoSmithKline
- 7.4.1 GlaxoSmithKline Company Information
- 7.4.2 GlaxoSmithKline Business Overview
- 7.4.3 GlaxoSmithKline Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.4.4 GlaxoSmithKline Live Vaccines Product Portfolio
- 7.4.5 GlaxoSmithKline Recent Developments
- 7.5 Pfizer
- 7.5.1 Pfizer Company Information
- 7.5.2 Pfizer Business Overview
- 7.5.3 Pfizer Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.5.4 Pfizer Live Vaccines Product Portfolio
- 7.5.5 Pfizer Recent Developments
- 7.6 Merck
- 7.6.1 Merck Company Information
- 7.6.2 Merck Business Overview
- 7.6.3 Merck Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.6.4 Merck Live Vaccines Product Portfolio
- 7.6.5 Merck Recent Developments
- 7.7 Novartis
- 7.7.1 Novartis Company Information
- 7.7.2 Novartis Business Overview
- 7.7.3 Novartis Live Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.7.4 Novartis Live Vaccines Product Portfolio
- 7.7.5 Novartis Recent Developments
8 North America
- 8.1 North America Live Vaccines Market Size by Type
- 8.1.1 North America Live Vaccines Revenue by Type (2021-2032)
- 8.1.2 North America Live Vaccines Sales by Type (2021-2032)
- 8.1.3 North America Live Vaccines Price by Type (2021-2032)
- 8.2 North America Live Vaccines Market Size by Application
- 8.2.1 North America Live Vaccines Revenue by Application (2021-2032)
- 8.2.2 North America Live Vaccines Sales by Application (2021-2032)
- 8.2.3 North America Live Vaccines Price by Application (2021-2032)
- 8.3 North America Live Vaccines Market Size by Country
- 8.3.1 North America Live Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Live Vaccines Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Live Vaccines Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
- 8.3.6 Mexico
9 Europe
- 9.1 Europe Live Vaccines Market Size by Type
- 9.1.1 Europe Live Vaccines Revenue by Type (2021-2032)
- 9.1.2 Europe Live Vaccines Sales by Type (2021-2032)
- 9.1.3 Europe Live Vaccines Price by Type (2021-2032)
- 9.2 Europe Live Vaccines Market Size by Application
- 9.2.1 Europe Live Vaccines Revenue by Application (2021-2032)
- 9.2.2 Europe Live Vaccines Sales by Application (2021-2032)
- 9.2.3 Europe Live Vaccines Price by Application (2021-2032)
- 9.3 Europe Live Vaccines Market Size by Country
- 9.3.1 Europe Live Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Live Vaccines Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Live Vaccines Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Russia
- 9.3.9 Spain
- 9.3.10 Netherlands
10 China
- 10.1 China Live Vaccines Market Size by Type
- 10.1.1 China Live Vaccines Revenue by Type (2021-2032)
- 10.1.2 China Live Vaccines Sales by Type (2021-2032)
- 10.1.3 China Live Vaccines Price by Type (2021-2032)
- 10.2 China Live Vaccines Market Size by Application
- 10.2.1 China Live Vaccines Revenue by Application (2021-2032)
- 10.2.2 China Live Vaccines Sales by Application (2021-2032)
- 10.2.3 China Live Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Live Vaccines Market Size by Type
- 11.1.1 Asia Live Vaccines Revenue by Type (2021-2032)
- 11.1.2 Asia Live Vaccines Sales by Type (2021-2032)
- 11.1.3 Asia Live Vaccines Price by Type (2021-2032)
- 11.2 Asia Live Vaccines Market Size by Application
- 11.2.1 Asia Live Vaccines Revenue by Application (2021-2032)
- 11.2.2 Asia Live Vaccines Sales by Application (2021-2032)
- 11.2.3 Asia Live Vaccines Price by Application (2021-2032)
- 11.3 Asia Live Vaccines Market Size by Country
- 11.3.1 Asia Live Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Live Vaccines Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Live Vaccines Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Live Vaccines Market Size by Type
- 12.1.1 SAMEA Live Vaccines Revenue by Type (2021-2032)
- 12.1.2 SAMEA Live Vaccines Sales by Type (2021-2032)
- 12.1.3 SAMEA Live Vaccines Price by Type (2021-2032)
- 12.2 SAMEA Live Vaccines Market Size by Application
- 12.2.1 SAMEA Live Vaccines Revenue by Application (2021-2032)
- 12.2.2 SAMEA Live Vaccines Sales by Application (2021-2032)
- 12.2.3 SAMEA Live Vaccines Price by Application (2021-2032)
- 12.3 SAMEA Live Vaccines Market Size by Country
- 12.3.1 SAMEA Live Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Live Vaccines Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Live Vaccines Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Live Vaccines Value Chain Analysis
- 13.1.1 Live Vaccines Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Live Vaccines Production Mode & Process
- 13.2 Live Vaccines Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Live Vaccines Distributors
- 13.2.3 Live Vaccines Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst